Dernières nouvelles pour Bristol-Myers Squibb (NYSE:BMY) Stock

BRISTOL-MYERS SQUIBB CO

Bristol-Myers Squibb

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb Co

BRISTOL-MYERS SQUIBB $2PR by Bristol-Myers Squibb Co.

Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is set to give its latest quarterly earnings report on Thursday, 2025-07-31. Here's what investors need to know before the announcement.
Analysts estimate that Bristol-Myers Squibb will report an earnings per share (EPS) of $1.15. 
Anticipation surrounds Bristol-Myers Squibb's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
The company's EPS beat by $0.31 in the last quarter, leading to a 1.62% drop in the share price on the following day.
Here's a look at Bristol-Myers Squibb's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.49</td>
<td>1.47</td>
<td>1.49</td>
<td>1.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.80</td>
<td>1.67</td>
<td>1.80</td>
<td>2.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-3.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753884122_0.png" alt="eps graph" />
<h3>Market Performance of Bristol-Myers Squibb's Stock</h3>
Shares of Bristol-Myers Squibb were trading at $46.86 as of July 29. Over the last 52-week period, shares are down 2.67%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Views on Bristol-Myers Squibb</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Bristol-Myers Squibb.
Analysts have given Bristol-Myers Squibb a total of 1 ratings, with the consensus rating being Underperform. The average one-year price target is $34.0, indicating a potential 27.44% downside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Zoetis, Teva Pharmaceutical Indus and Viatris, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Zoetis, with an average 1-year price target of $173.75, suggesting a potential 270.79% upside.</li>
<li>Analysts currently favor an Buy trajectory for Teva Pharmaceutical Indus, with an average 1-year price target of $23.4, suggesting a potential 50.06% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Viatris, with an average 1-year price target of $10.0, suggesting a potential 78.66% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Zoetis, Teva Pharmaceutical Indus and Viatris, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bristol-Myers Squibb</td>
<td>Underperform</td>
<td>-5.60%</td>
<td>$8.17B</td>
<td>14.57%</td>
</tr>
<tr>
<td>Zoetis</td>
<td>Neutral</td>
<td>1.37%</td>
<td>$1.60B</td>
<td>13.39%</td>
</tr>
<tr>
<td>Teva Pharmaceutical Indus</td>
<td>Buy</td>
<td>1.89%</td>
<td>$1.88B</td>
<td>3.68%</td>
</tr>
<tr>
<td>Viatris</td>
<td>Neutral</td>
<td>-11.17%</td>
<td>$1.16B</td>
<td>-17.74%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Bristol-Myers Squibb ranks at the bottom for revenue growth and gross profit, while it is in the middle for return on equity. The consensus rating for the company is 'Underperform'.
<h3>Get to Know Bristol-Myers Squibb Better</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
<h3>Bristol-Myers Squibb: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Bristol-Myers Squibb's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -5.6%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bristol-Myers Squibb's net margin excels beyond industry benchmarks, reaching 21.93%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bristol-Myers Squibb's ROE stands out, surpassing industry averages. With an impressive ROE of 14.57%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bristol-Myers Squibb's ROA stands out, surpassing industry averages. With an impressive ROA of 2.65%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.95, Bristol-Myers Squibb faces challenges in effectively managing its debt levels, indicating potential financial strain.
<a href="https://www.benzinga.com/quote/BMY/earnings">To track all earnings releases for Bristol-Myers Squibb visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Bristol-Myers Squibb Earnings Preview

<ul>
<li>Five immunology assets in-licensed from BMS with potential to address unmet needs for patients with autoimmune diseases, including late-stage asset for lupus</li>
<li>Bain Capital leads $300 million financing commitment</li>
</ul>
Bristol Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>, "BMS"))) and Bain Capital today announced the creation of a new independent biopharmaceutical company ("NewCo") focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital.
The NewCo has a broad pipeline consisting of three clinical-stage and two Phase 1-ready investigational medicines that each target promising mechanisms in autoimmune diseases. The most advanced assets in the NewCo's portfolio are afimetoran, an oral, potential best-in-class TLR7/8 inhibitor that is currently being studied in a Phase 2 clinical trial for systemic lupus erythematosus (SLE), and BMS-986322, an oral TYK2 inhibitor, which successfully established proof-of-concept in a positive plaque psoriasis Phase 2 trial. Other licensed assets include BMS-986326, a novel, potential best-in-class, IL2 fusion protein that is currently being studied in Phase 1 clinical trials for SLE and atopic dermatitis, and BMS-986481 and BMS-986498, two Phase 1-ready biologics targeting the IL18 and IL10 pathways respectively.
The assets licensed to NewCo reflect the strength of BMS's scientific innovation and hold promise to address unmet needs for patients with autoimmune diseases. As part of the agreement, BMS will retain a nearly 20 percent equity stake in NewCo and will be entitled to royalties and milestones tied to the success of each asset. Robert Plenge, MD, PhD, Executive Vice President and Chief Research Officer at BMS, will also serve on NewCo's Board of Directors. This transaction reflects BMS's strategic shift in Immunology research to focus on assets that have the potential to reset the immune system and promote tissue repair. It also further demonstrates the company's sharpened strategy to invest in areas where BMS is best positioned to lead, while enabling the continued development of promising medicines.

Biotech

News

Contracts

General

Bristol Myers And Bain Capital Launch $300M Autoimmune Biotech With 5 In-Licensed Immunology Assets, Including Late-Stage Lupus Drug

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings <a href="https://www.benzinga.com/general/biotech">from its latest clinical trial.</a>
Recognify Life Sciences announced data from a randomized, double-blind, placebo-controlled Phase 2b trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">associated with schizophrenia (CIAS)</a>. Recognify is a strategic investment of ATAI Life Sciences N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>).
<ul class="wp-block-list">
<li>ATAI stock is tumbling in today&#8217;s session. <a href="https://www.benzinga.com/quote/ATAI" target="_blank" rel="noreferrer noopener">Check the price action here.</a></li>
</ul>
The trial did not meet its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6.
Also Read: <a target="_blank" href="https://www.benzinga.com/cannabis/25/07/46194289/atai-life-sciences-and-merger-partner-set-up-psychedelic-depression-therapy-with-encouraging-late-stage-data" rel="noreferrer noopener">Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data</a>
The company on Monday said the inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing, and Verbal Learning<a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46643996/recognify-life-sciences-provides-update-on-phase-2b-trial-of-inidascamine-in-patients-with-cogniti" rel="noreferrer noopener"> (immediate recall)</a>.
Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a real-world functional <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio" rel="noreferrer noopener">cognitive capacity measure</a>.
Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies.
No evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with schizophrenia treatments.
The study enrolled 242 patients.
Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data.
In November 2024, AbbVie&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41884798/abbvies-emraclidine-for-schizophrenia-surprisingly-disappoints-analyst-says-pipeline-is-underappreciated" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
In September 2024, the FDA approved Bristol Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for <a href="https://www.benzinga.com/pressreleases/24/09/b41059140/u-s-food-and-drug-administration-approves-bristol-myers-squibbs-cobenfy-xanomeline-and-trospium-ch" target="_blank" rel="noreferrer noopener">schizophrenia in adults</a>.
Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1&nbsp;and M4&nbsp;receptors in the brain without blocking D2&nbsp;receptors.
ATAI Price Action: ATAI Life Sciences shares were down 9.38% at $3.23 at the time of publication on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/07/46657092/can-american-airlines-navigate-financial-turbulence-ahead" target="_blank" rel="noreferrer noopener">Can American Airlines Navigate Financial Turbulence Ahead?</a></li>
</ul>
Photo: Shutterstock

Health Care

Movers

Trading Ideas

ABBV

ATAI

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Investor sentiment around several major stocks got a boost this week thanks to upbeat commentary from Jim Cramer <a href="https://www.benzinga.com/topic/jim-cramer">and fresh analyst support</a>.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Cramer praised both Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) and CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>).
&#8220;Marvin Ellison [CEO of Lowe&#8217;s] is hitting the ball,&#8221; Cramer added <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">with a buy recommendation</a>. &#8220;He's doing his best.&#8221;
Supporting his view, Guggenheim analyst Steven Forbes, on July 22, reiterated Lowe&#8217;s Companies with a Buy and maintained a $300 price target.
When asked about CrowdStrike, he said, &#8220;Take out your cost basis, and then you're going to let the rest run. And I'll see you at $1000.&#8221;
Macquarie analyst Steve Koenig, on July 17, initiated coverage on CrowdStrike with a Neutral rating and announced a price target of $465.
&#8220;We're still on the verge of finding out what this Seagen acquisition does,&#8221; Cramer said when asked about Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). &#8220;Let's give Dr. Bourla [CEO of Pfizer] two more quarters.&#8221;
As per the recent news, Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer alliance, on July 17, announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on Thursday. Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.
Price Action:
<ul class="wp-block-list">
<li>Pfizer shares gained 0.9% to settle at $25.36 on Wednesday.</li>
<li>CrowdStrike shares fell 2.1% to close at $461.52.</li>
<li>Lowe's shares gained 1.3% to settle at $228.61 on Wednesday.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46570034/jim-cramer-likes-stocks-yield-not-fundamentals">Jim Cramer Loves &#8216;That Yield&#8217; But Passes On This Stock: &#8216;Fundamentals Are Hurting&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

CRWD

Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000'

Bristol-Myers Squibb's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) short percent of float has risen 17.58% since its last report. The company recently reported that it has 39.45 million shares sold short, which is 1.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Bristol-Myers Squibb Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753300828_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Bristol-Myers Squibb has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Bristol-Myers Squibb's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Bristol-Myers Squibb's Recent Short Interest

In the current session, the stock is trading at $46.90, after a 0.45% spike. Over the past month, Bristol-Myers Squibb Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) stock increased by 1.92%, and in the past year, by 7.33%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1753210824_0.png" alt="Past Year Chart" />

<h3>A Look at Bristol-Myers Squibb P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 29.12 in the Pharmaceuticals industry, Bristol-Myers Squibb Inc. has a lower P/E ratio of 17.42. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1753210824_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Bristol-Myers Squibb Inc's Price Over Earnings

AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) announced on Tuesday that it will invest $50 billion in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">United States by 2030</a>.
The investment will create new, highly skilled direct and indirect jobs nationwide, the company <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/astrazeneca-plans-to-invest-50bn-dollars-in-the-us.html" rel="noreferrer noopener">said</a>.
The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products.
The new centre will produce small molecules, peptides, and oligonucleotides.
This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.
The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production.
<h2 class="wp-block-heading">What Does The Investment Include?</h2>
The $50 billion investment across R&amp;D and manufacturing footprint in the U.S. over the next five years also includes:
<ul class="wp-block-list">
<li>Expansion of R&amp;D facility in Gaithersburg, Maryland</li>
<li>R&amp;D centre in Kendall Square, Cambridge, Massachusetts</li>
<li>Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California</li>
<li>Manufacturing expansion in Mount Vernon, Indiana</li>
<li>Specialty manufacturing expansion in Coppell, Texas</li>
<li>New sites to supply clinical trials.</li>
</ul>
The company said collectively, these investments will help deliver AstraZeneca's <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38936595/astrazeneca-targets-ambitious-80b-in-total-revenue-by-2030-through-pipeline-expansion" rel="noreferrer noopener">ambition of reaching $80 billion</a> in Total Revenue by 2030, of which 50% would be generated in the U.S.
Howard Lutnick, U.S. Secretary of Commerce, said: "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores."
<a target="_blank" href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S. Most recently, Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) said that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46529101/biogen-bets-big-on-2-billion-expansion-to-boost-us-drug-manufacturing" rel="noreferrer noopener">Triangle Park (RTP)</a>.
Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" rel="noreferrer noopener">domestic medicine production</a>.
Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" rel="noreferrer noopener">the next four years</a>.
Medtech firm&nbsp;Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" rel="noreferrer noopener">over the next five years</a>.
Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>. Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S.&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" rel="noreferrer noopener">over the next five years</a>.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>. Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/pharmaceuticals" rel="noreferrer noopener">the next five years.</a>
Bristol-Myers Squibb &amp; Co.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer,&nbsp;<a target="_blank" href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years. Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced it will invest at least&nbsp;$20 billion&nbsp;in&nbsp;the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45419235/sanofi-joins-other-big-pharma-to-navigate-potential-tariff-impact-with-at-least-20-billion-in-investments-through-2030" rel="noreferrer noopener">U.S.&nbsp;through 2030</a>. The bulk of the spending will go to R&amp;D and U.S. manufacturing.
Price Action: AZN stock is up 2.34% at $70.33 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46551856/pony-ai-stock-surges-as-autonomous-system-hits-key-milestone" target="_blank" rel="noreferrer noopener">Pony AI Stock Surges As Autonomous System Hits Key Milestone</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Large Cap

BIIB

REGN

RHHBY

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock plunged on Tuesday after a U.S. Food and Drug Administration <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">(FDA) update</a>.
The clinical stage biotechnology company received an FDA Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with Bristol-Myers&nbsp;Squibb&nbsp;Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo (nivolumab) for advanced melanoma.
The CRL indicates that the FDA cannot approve the application in its present form.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46507574/bill-gates-warns-us-cuts-to-tb-aid-could-lead-to-2-million-additional-deaths-worldwide" rel="noreferrer noopener">Bill Gates Warns US Cuts To TB Aid Could Lead To 2 Million Additional Deaths Worldwide</a>
The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46539842/replimune-receives-complete-response-letter-from-fda-for-rp1-biologics-license-application-for-the" rel="noreferrer noopener">evidence of effectiveness</a>.
Furthermore, the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.
The CRL also states that items related to the confirmatory trial study design, including the contribution of components, need to be addressed. No safety issues were raised.
The company will request a Type A meeting and expects it to be granted within 30 days.
Replimune plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of RP1, without which the development of RP1 for advanced cancer patients with limited options will not be viable.
&#8220;We are surprised by this FDA decision and disappointed&#8230;,&#8221; said Sushil Patel, Ph.D., Chief Executive Officer, Replimune. &#8220;The issues highlighted in the CRL were not raised by the agency during the mid- and late-cycle reviews. Additionally, we had also aligned on the design of the confirmatory study. We strongly believe that RP1 combined with nivolumab can substantially benefit advanced melanoma patients.&#8221;
Replimune presented two posters highlighting data updates for RP1 at the 2025 American Society of Clinical Oncology <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45712014/replimune-presents-new-analyses-from-the-ignyte-study-of-rp1-plus-nivolumab-in-anti-pd1-failed-mel" rel="noreferrer noopener">Annual Meeting in June</a>.
The poster included an analysis from the IGNYTE clinical trial of RP1 plus nivolumab in the cohort of anti-PD-1 failed melanoma patients (n=140).
In the trial, the objective response rate (ORR) was 32.9%. The complete response rate was 15.0% and landmark overall survival (OS) rates at 1, 2, and 3 years were 75.3%, 63.3%, and 54.8% respectively. The median OS has not been reached.
RP1 injections directly into the lung and liver were generally well tolerated, resulting in few organ-specific adverse events that were easily managed.
No bleeding events were reported after liver injection. RP1 was assessed in various patient samples, demonstrating that RP1 DNA is primarily detected at the injection site, consistent with RP1 replication in the tumor, and much more rarely on dressings, in blood, on mucous membranes, or in urine.
Price Action: REPL stock is down 74.80% at $3.11 at the last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46542820/general-motors-faces-tariffs-heat-margins-shrink" target="_blank" rel="noreferrer noopener">General Motors Faces Tariffs Heat, Margins Shrink</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

REPL

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.03%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and slashed the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: The Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on July 17.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PFE <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="907" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272.png" alt="" class="wp-image-993503" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272-768x699.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.29%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $67 to $71 on May 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31, to discuss second quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CVS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273.png" alt="" class="wp-image-993506" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.47%</li>
<li>Citigroup analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $210 to $205 on May 14, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Guggenheim analyst Vamil Divan maintained a Buy rating and increased the price target from $214 to $216 on April 29, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: GI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie, on July 10, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest ABBV <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="910" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274.png" alt="" class="wp-image-993508" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274-768x699.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Analyst Ratings

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Applications supported by positive results from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials, in which significantly more patients treated with Sotyktu achieved ACR20 response compared with placebo at Week 16
U.S. Food and Drug Administration assigned a target action date of March 6, 2026
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bms.com%2F&amp;esheet=54292059&amp;newsitemid=20250717182422&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=ef159a533b38560d13828afd7ec80b1e">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026. This latest regulatory milestone is in addition to the sNDA acceptances by China's Center for Drug Evaluation of National Medical Products Administration and Japan's Ministry of Health, Labour and Welfare for Sotyktu for the treatment of adults with active psoriatic arthritis. The European Medicines Agency has also validated Bristol Myers Squibb's Type II variation application to expand the indication for Sotyktu to include this disease.
Sotyktu received approval from the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Since then, Sotyktu has earned approvals for this indication from multiple global health authorities and demonstrated durable efficacy and a consistent safety profile over more than 20,000 patient-years of experience.
Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, has the potential to be the first TYK2 inhibitor for the treatment of psoriatic arthritis.
The regulatory applications are based on positive results from the pivotal POETYK PsA-1 and POETYK PsA-2 trials, which evaluated the efficacy and safety of Sotyktu in adults with active psoriatic arthritis. Both trials met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving ACR20 response (at least a 20 percent improvement in signs and symptoms of disease) after 16 weeks of treatment compared with placebo. Additional data from POETYK PsA-2 reported outcomes through 52 weeks of treatment and demonstrated that clinical response improved and was maintained from Weeks 16 to 52.
The overall safety profile of Sotyktu through 16 weeks of treatment in the POETYK PsA-1 and POETYK PsA-2 trials was consistent with that established in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials; no new safety signals were observed. Initial results from the POETYK PsA-2 trial were presented at the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fcorporate-financial%2F2025%2FBristol-Myers-Squibb-Presents-Late-Breaking-Data-from-Phase-3-POETYK-PsA-2-Trial-Demonstrating-Superiority-of-Sotyktu-deucravacitinib-Compared-with-Placebo-in-Adults-with-Psoriatic-Arthritis%2Fdefault.aspx&amp;esheet=54292059&amp;newsitemid=20250717182422&amp;lan=en-US&amp;anchor=2025+American+Academy+of+Dermatology+%28AAD%29+Annual+Meeting&amp;index=3&amp;md5=d2f570b650c63e3e139b7bfea0a983bd">2025 American Academy of Dermatology (AAD) Annual Meeting</a> in March 2025. Data from both POETYK PsA-1 and POETYK PsA-2 were presented at the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.bms.com%2Fnews%2Fdetails%2F2025%2FBristol-Myers-Squibb-Presents-Late-Breaking-Data-from-Pivotal-Phase-3-POETYK-PsA-1-Trial-Demonstrating-Superiority-of-Sotyktu-deucravacitinib-Compared-with-Placebo-in-Adults-with-Psoriatic-Arthritis%2Fdefault.aspx&amp;esheet=54292059&amp;newsitemid=20250717182422&amp;lan=en-US&amp;anchor=European+Alliance+of+Associations+for+Rheumatology+%28EULAR%29&amp;index=4&amp;md5=b09f92109f26a6956d7d4f0316573f67">European Alliance of Associations for Rheumatology (EULAR)</a> Congress in June 2025; additional results will be presented at future scientific meetings.

FDA Accepts Bristol Myers Squibb's sNDA For Sotyktu For Treatment Of Adults With Active Psoriatic Arthritis For Review

Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">red blood cell (RBC) transfusions</a>.
The study did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674).
Patients saw a numerical and clinically meaningful improvement in RBC transfusion independence favoring Reblozyl, in line with previous results <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46488740/bristol-myers-squibb-announces-topline-results-from-phase-3-independence-trial-for-reblozyl-luspat" rel="noreferrer noopener">from the Phase 2 trial</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46478200/bristol%e2%80%91myers-squibb-pfizer-set-to-launch-direct%e2%80%91to%e2%80%91patient-eliquis-at-40-off" rel="noreferrer noopener">Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off</a>
Several key secondary measures also showed a clinically meaningful benefit favoring Reblozyl, which included a higher number of patients who achieved at least a 50% reduction (and by at least 4 RBC units) in RBC transfusion burden, as well as a higher number of patients achieving a hemoglobin (Hb) level increase by at least 1 g/dL while remaining transfusion independent for at least 12 consecutive weeks.
Frequently observed treatment-emergent adverse events were consistent with Reblozyl&#8217;s previously reported safety profile across indications. The company will engage with the FDA and EMA to discuss the submission of marketing applications.
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require RBC transfusions, failing an erythropoiesis stimulating agent and requiring two or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis, and treatment of anemia in adult patients with beta thalassemia who require RBC transfusions.
Price Action: BMY stock is trading lower by 1.40% to $47.39 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46490461/autolivs-q2-pops-on-solid-tariff-recovery-but-china-overhang-pressures-stock" target="_blank" rel="noreferrer noopener">Autoliv&#8217;s Q2 Pops On Solid Tariff Recovery, But China Overhang Pressures Stock</a></li>
</ul>
Photo via Shutterstock

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54292459&amp;newsitemid=20250717218246&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=11347020056e3dfcf47ccb9b4ccb9302">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl&#xAE;(luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell (RBC) transfusions did not meet its primary endpoint of RBC transfusion independence during any consecutive 12-week period, starting within the first 24 weeks of treatment, compared to placebo (p=0.0674). Patients saw a numerical and clinically meaningful improvement in RBC transfusion independence favoring Reblozyl, in line with previous results from the Phase 2 trial (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT03194542%3Fcond%3Dmyelofibrosis%26term%3Dluspatercept%26checkSpell%3D%26rank%3D3&amp;esheet=54292459&amp;newsitemid=20250717218246&amp;lan=en-US&amp;anchor=NCT03194542&amp;index=2&amp;md5=4f18f4ee81c128936c5bbe7b293149ac">NCT03194542</a>).
Several important secondary measures also showed a clinically meaningful benefit favoring Reblozyl, which included a higher number of patients who achieved at least a 50% reduction (and by at least 4 RBC units) in RBC transfusion burden, as well as a higher number of patients achieving a hemoglobin (Hb) level increase by at least 1 g/dL while remaining transfusion independent for at least 12 consecutive weeks.
Frequently observed treatment emergent adverse events were consistent with the known safety profile of Reblozyl previously reported across indications.
The company is encouraged by the clinically meaningful results of the study and will engage with the FDA and EMA to discuss the submission of marketing applications.
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require RBC transfusions, treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T), and treatment of anemia in adult patients with beta thalassemia who require RBC transfusions.
Bristol Myers Squibb thanks the patients, investigators and clinical trial sites who participated in the INDEPENDENCE clinical trial.

Bristol Myers Squibb Reports Phase 3 INDEPENDENCE Trial Misses Primary Endpoint In Myelofibrosis-Related Anemia Treatment

The Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance&#8217;s patient resource, Eliquis 360 <a href="https://www.benzinga.com/general/health-care">Support, on Thursday.</a>
Eliquis is a blood-thinning medication that reduces blood clotting and prevents strokes.
In May 2024, Pfizer said it is&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38595739/pfizer-prospects-garner-mixed-sentiment-from-analysts-finally-the-pivot-investors-h" rel="noreferrer noopener">looking to build</a> on the success of its&nbsp;COVID-19&nbsp;vaccine rollout by introducing a direct-to-consumer medicines platform under the brand "Pfizer for All."&nbsp;
In August 2024, Pfizer introduced&nbsp;the PfizerForAll&nbsp;<a target="_blank" href="https://www.benzinga.com/insights/options/25/03/44202700/pfizers-options-a-look-at-what-the-big-money-is-thinking" rel="noreferrer noopener">digital platform in collaboration</a> with UpScriptHealth, Alto Pharmacy, and Instacart.
The move, as reflected in a recent trademark application, aims to provide medical information, mail-order pharmacy services, and telehealth <a href="https://www.benzinga.com/top-stories/24/05/38798101/pfizer-follows-eli-lillys-footsteps-to-sell-medicines-directly-to-patients" target="_blank" rel="noreferrer noopener">services to US patients</a>.
The offering provides an opportunity for uninsured, underinsured, or self-pay patients to lower their <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46462973/bristol-myers-squibb-and-pfizer-announce-direct-to-patient-eliquis-apixaban-option" rel="noreferrer noopener">out-of-pocket costs</a>.
Beginning Sept. 8, eligible U.S. patients with an Eliquis prescription may purchase the medicine directly through Eliquis 360 Support. They will pay a discounted rate of more than 40% less than the current list price.
The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated costs.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46400278/is-bristol-myers-squibb-still-an-undervalued-biopharma-play" rel="noreferrer noopener">Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?</a>
With more than 15 million Americans having been prescribed Eliquis since its launch, the medicine has resulted in an estimated $3 billion in total healthcare cost savings and avoidance, including hospitalization and extended rehabilitation needs, for every 100,000 patients treated.
The Wall Street Journal was the first to <a target="_blank" href="http://www.wsj.com/health/pharma/bristol-myers-and-pfizer-to-offer-blockbuster-blood-thinner-at-discount-3c0513ef" rel="noreferrer noopener">report</a> the update.
The report, citing a source, stated that the Bristol-Pfizer partnership opted to launch direct sales of Eliquis following discussions with the Trump administration about making the drug more affordable.
Eliquis, which normally costs $606 for a 30-day supply, will now be sold directly to patients for a reduced cash price of $346 per month.
In the past, drugmakers didn't sell their medicines straight to consumers. Instead, they used middlemen called wholesalers to distribute the drugs and depended on insurance companies to cover most of the costs.
In January 2024, drugmaker Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) became the first to launch a new website allowing patients to get a prescription for weight loss <a href="https://www.benzinga.com/general/biotech/24/01/36495250/eli-lilly-launches-website-to-help-patients-with-home-delivery-options-for-weight-loss-medicines" target="_blank" rel="noreferrer noopener">through a telehealth provider</a>.
LillyDirect&nbsp;offers disease management resources, including access to independent healthcare providers, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services.
In March 2025, in a letter addressed to UpScriptHealth CEO Peter Ax, senators expressed concern about the financial relationship between Pfizer and UpScriptHealth, given its potential implications for the federal <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44311862/pfizers-direct-to-consumer-model-faces-scrutiny-from-us-senators" rel="noreferrer noopener">Anti-Kickback Statute (AKS)</a>.
The letter states that the PfizerForAll program, funded by the drugmaker, appears to be designed to direct patients toward specific drugs, which could lead to unnecessary prescriptions and higher costs for federal healthcare programs.
The letter notes that pharmaceutical companies, including Pfizer, spend approximately $6 billion annually on Direct-to-consumer (DTC) advertising.
Price Action: PFE stock is down 0.08% at $24.59, and BMY stock is up 1.51% at $47.88 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/technicals/25/07/46476087/netflix-bulls-are-winning-the-binge-but-is-a-plot-twist-coming-after-earnings" target="_blank" rel="noreferrer noopener">Netflix Bulls Are Winning The Binge — But Is A Plot Twist Coming After Earnings?</a></li>
</ul>
Photo: Shutterstock

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off

Eliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price
The Bristol Myers Squibb-Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) – (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Alliance today announced a new direct-to-patient option for purchasing Eliquis&#xAE;(apixaban) via our Alliance's patient resource <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eliquis.bmscustomerconnect.com%2Fsupport&amp;esheet=54291954&amp;newsitemid=20250717718933&amp;lan=en-US&amp;anchor=Eliquis+360+Support&amp;index=1&amp;md5=85171b9ae54f9ac290bb5d3cbcc6e3ef">Eliquis 360 Support</a>. The offering provides an opportunity for uninsured, underinsured, or self-pay patients to significantly lower their out-of-pocket costs for this critical medicine. Eliquis is relied upon by millions of Americans daily and this program will provide a simple and transparent way to access it.

Bristol Myers Squibb-Pfizer Alliance Announce New Direct-To-Patient Option For Purchasing Eliquis Via Alliance's Patient Resource Eliquis 360 Support

The Wall Street Journal Reported Bristol-Myers Squibb and Pfizer to Launch Direct-to-Consumer Sales of Eliquis

Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BMY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Bristol-Myers Squibb. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 3 are puts, totaling $202,924, and 6 are calls, amounting to $320,715.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $46.0 and $50.0 for Bristol-Myers Squibb, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Bristol-Myers Squibb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Bristol-Myers Squibb's significant trades, within a strike price range of $46.0 to $50.0, over the past month.
<h3>Bristol-Myers Squibb 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752595254_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.55</td>
<td>$46.00</td>
<td>$150.9K</td>
<td>175</td>
<td align="right">426</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.05</td>
<td>$2.87</td>
<td>$2.9</td>
<td>$50.00</td>
<td>$130.7K</td>
<td>6.7K</td>
<td align="right">500</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/29/25</td>
<td>$1.31</td>
<td>$1.2</td>
<td>$1.2</td>
<td>$49.00</td>
<td>$54.0K</td>
<td>6</td>
<td align="right">450</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$1.37</td>
<td>$1.35</td>
<td>$1.35</td>
<td>$50.00</td>
<td>$37.6K</td>
<td>6.7K</td>
<td align="right">342</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$2.51</td>
<td>$2.44</td>
<td>$2.51</td>
<td>$48.00</td>
<td>$37.6K</td>
<td>656</td>
<td align="right">150</td>
</tr>
</tbody>
</table>

<h3>About Bristol-Myers Squibb</h3>
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
In light of the recent options history for Bristol-Myers Squibb, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Bristol-Myers Squibb Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 5,984,142, the BMY's price is down by -0.19%, now at $47.25. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 16 days.</li>
</ul>
<h3>Expert Opinions on Bristol-Myers Squibb</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $34.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on Bristol-Myers Squibb, maintaining a target price of $34. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bristol-Myers Squibb options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

A Closer Look at Bristol-Myers Squibb's Options Market Dynamics

Bristol-Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is gearing up to announce its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45900314/bristol-myers-squibb-to-report-results-for-second-quarter-2025-on-july-31-2025" rel="noreferrer noopener">second-quarter 2025</a> earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, according to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
While revenue and underlying earnings per share estimates for the current quarter and full-year 2025 have seen slight downward revisions, the U.S. pharma giant anticipates a low-single-digit percentage increase in total revenue for the later 2020s, primarily driven by updated assumptions for its cancer drug Yervoy.
The upcoming earnings call is expected to shed light on the performance of key products, future milestones, and the impact of U.S. drug pricing policies on the broader industry.
Read Next: <a target="_blank" href="https://www.benzinga.com/news/legal/25/06/46098969/bristol-myers-faces-scrutiny-for-allegedly-rigging-market-on-2b-cancer-drug" rel="noreferrer noopener">Bristol Myers Faces Scrutiny For Allegedly Rigging Market On $2 Billion Cancer Drug</a>
Bank of America Securities (BofA) updated the company&#8217;s earnings model. For the second quarter, BofA&#8217;s total revenue estimates and EPS decline by more than 1%, with no significant changes; for 2025, there are no major changes, revenue and underlying earnings per share decrease by more than 1%.
For the later 2020s, total revenue estimates increase by a low-single-digit percentage, primarily related to updated loss-of-exclusivity assumptions for Yervoy. BofA maintains a Neutral rating <a target="_blank" href="https://www.benzinga.com/quote/BMY/analyst-ratings" rel="noreferrer noopener">and a price forecast of $56</a>, using an 8x P/E multiple on updated 2025E EPS.
Analyst Tim Anderson notes that while Bristol-Myers Squibb has described the Inflation Reduction Act&#8217;s (IRA) Medicare Part D reform as &#8220;potentially net neutral across the portfolio,&#8221; certain products like Pomalyst, Revlimid, Camzyos, and Orencia (subcutaneous) are expected to have greater headwinds.
As the upcoming earnings call approaches, investors and analysts will be keenly focused on a few critical areas that will shape Bristol Myers Squibb&#8217;s narrative.
A significant portion of the discussion is anticipated to revolve around the evolving landscape of U.S. drug pricing policies. The specter of initiatives like the &#8216;most favored nation&#8217; rule, alongside the potential imposition of pharma-specific tariffs under Section 232, casts a long shadow over the entire pharmaceutical industry, and Bristol Myers Squibb is certainly not immune to these systemic pressures.
Beyond these broader industry concerns, the call will undoubtedly provide crucial updates on the commercial performance and future potential of key products within the company&#8217;s portfolio, including Cobenfy, Camzyos, Reblozyl, and Breyanzi.
Their trajectory in the market will be a strong indicator of the company&#8217;s immediate revenue streams. Additionally, stakeholders will be eager to hear about upcoming milestones slated for 2025, which could provide insights into future product launches, regulatory decisions, or significant clinical trial readouts.
While the company navigates these operational and policy challenges, its valuation remains a talking point among analysts. As analyst Anderson points out, Bristol Myers Squibb &#8220;remains one of the cheaper companies in large-cap biopharma,&#8221; but it&#8217;s no longer unusually cheap. Its price-to-earnings ratio of 7 to 8 times expected 2025 earnings is now similar to peers like Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and Merck &amp; Co. Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
Despite this current valuation, the road ahead appears challenging. The company is bracing for several tough years, with an anticipated decline in earnings primarily driven by the relentless pressure from generic competition.
This looming threat to its established revenue streams means that achieving meaningful medium-term growth will be a significant hurdle for Bristol Myers Squibb to overcome.
Price Action: BMY stock is trading higher by 1.52% to $47.57 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46396595/jpmorgan-citi-to-kick-off-bank-earnings-as-wall-street-sees-profit-boom" target="_blank" rel="noreferrer noopener">JPMorgan, Citi To Kick Off Bank Earnings As Wall Street Sees Profit Boom</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Reiteration

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?

WIIM

GILD

Shares of drug stocks are trading lower after the FDA reportedly indicated it could fast track drugs to companies that cut US prices in line with other countries.

MiNK Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock is trading higher on Friday, with a session volume of 20.2 million compared to the average volume of 7.5 million <a href="https://www.benzinga.com/pro/feature/newsfeed" target="_blank" rel="noreferrer noopener">as per data from Benzinga Pro</a>.
The clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies announced the publication of yet another landmark case in Nature&#8217;s Oncogene describing a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer, following treatment with agenT-797, MiNK&#8217;s <a href="https://www.benzinga.com/pressreleases/25/07/g46363504/mink-therapeutics-announces-publication-of-complete-remission-following-allogeneic-inkt-cell-thera" target="_blank" rel="noreferrer noopener">allogeneic iNKT cell therapy</a>.
What happened: The patient had progressed despite multiple lines of therapy and received a single infusion of agenT-797 in combination with Bristol-Myers Squibb Company&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo (nivolumab).
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details" rel="noreferrer noopener">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a>
The patient achieved a complete clinical, radiologic and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post-infusion; treatment was well-tolerated with no cytokine release syndrome (CRS) or <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">graft-versus-host disease (GVHD)</a>.
These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors.
At the 2025 inaugural AACR Immuno-Oncology meeting, MiNK presented data from its Phase 2 trial in 2L gastric cancer, demonstrating immune activation, increased tumor infiltration and early signals of tumor control in patients previously refractory to checkpoint inhibitors.
Several patients experienced extended survival beyond 12 months.
These clinical observations were further reinforced in a separate peer-reviewed case report published in Oncogene, which described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival following a single infusion of agenT-797 in combination with nivolumab.
The ongoing Phase 2 trial in gastric cancer is actively enrolling, and additional readouts are expected in the upcoming months.
Price Action: INKT stock is up 471.3% to $44.16 as of the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46367694/gorilla-technology-targets-1-3-billion-in-new-contracts-by-mid-2026" target="_blank" rel="noreferrer noopener">Gorilla Technology Targets $1.3 Billion In New Contracts By Mid-2026</a></li>
</ul>
Photo: Shutterstock

INKT

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

Equities

AMGN

AMZN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Press Releases

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

Bristol Myers Squibb Announces Dividend

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Bristol-Myers Squibb

Actualités

Dernières nouvelles pour Bristol-Myers Squibb (NYSE:BMY) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL